229 related articles for article (PubMed ID: 33606104)
1. Clinical results of fibroblast activation protein (FAP) specific PET for non-malignant indications: systematic review.
Windisch P; Zwahlen DR; Giesel FL; Scholz E; Lugenbiel P; Debus J; Haberkorn U; Adeberg S
EJNMMI Res; 2021 Feb; 11(1):18. PubMed ID: 33606104
[TBL] [Abstract][Full Text] [Related]
2. Clinical Results of Fibroblast Activation Protein (FAP) Specific PET and Implications for Radiotherapy Planning: Systematic Review.
Windisch P; Zwahlen DR; Koerber SA; Giesel FL; Debus J; Haberkorn U; Adeberg S
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32942573
[TBL] [Abstract][Full Text] [Related]
3. Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging.
Schmidkonz C; Rauber S; Atzinger A; Agarwal R; Götz TI; Soare A; Cordes M; Prante O; Bergmann C; Kleyer A; Ritt P; Maschauer S; Hennig P; Toms J; Köhner M; Manger B; Stone JH; Haberkorn U; Baeuerle T; Distler JHW; Agaimy A; Kuwert T; Schett G; Ramming A
Ann Rheum Dis; 2020 Nov; 79(11):1485-1491. PubMed ID: 32719042
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic yield of FAP-guided positron emission tomography in thyroid cancer: a systematic review.
Rizzo A; Albano D; Dondi F; Cioffi M; Muoio B; Annunziata S; Racca M; Bertagna F; Piccardo A; Treglia G
Front Med (Lausanne); 2024; 11():1381863. PubMed ID: 38590320
[TBL] [Abstract][Full Text] [Related]
5. Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an
Toms J; Kogler J; Maschauer S; Daniel C; Schmidkonz C; Kuwert T; Prante O
J Nucl Med; 2020 Dec; 61(12):1806-1813. PubMed ID: 32332144
[TBL] [Abstract][Full Text] [Related]
6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
7. IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT.
Röhrich M; Loktev A; Wefers AK; Altmann A; Paech D; Adeberg S; Windisch P; Hielscher T; Flechsig P; Floca R; Leitz D; Schuster JP; Huber PE; Debus J; von Deimling A; Lindner T; Haberkorn U
Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2569-2580. PubMed ID: 31388723
[TBL] [Abstract][Full Text] [Related]
8.
Giesel FL; Kratochwil C; Lindner T; Marschalek MM; Loktev A; Lehnert W; Debus J; Jäger D; Flechsig P; Altmann A; Mier W; Haberkorn U
J Nucl Med; 2019 Mar; 60(3):386-392. PubMed ID: 30072500
[TBL] [Abstract][Full Text] [Related]
9. FAP-specific PET signaling shows a moderately positive correlation with relative CBV and no correlation with ADC in 13 IDH wildtype glioblastomas.
Röhrich M; Floca R; Loi L; Adeberg S; Windisch P; Giesel FL; Kratochwil C; Flechsig P; Rathke H; Lindner T; Loktev A; Schlemmer HP; Haberkorn U; Paech D
Eur J Radiol; 2020 Jun; 127():109021. PubMed ID: 32344293
[TBL] [Abstract][Full Text] [Related]
10. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
[TBL] [Abstract][Full Text] [Related]
11. Molecular Imaging of Fibroblast Activity After Myocardial Infarction Using a
Varasteh Z; Mohanta S; Robu S; Braeuer M; Li Y; Omidvari N; Topping G; Sun T; Nekolla SG; Richter A; Weber C; Habenicht A; Haberkorn UA; Weber WA
J Nucl Med; 2019 Dec; 60(12):1743-1749. PubMed ID: 31405922
[TBL] [Abstract][Full Text] [Related]
12. Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein.
Lindner T; Loktev A; Altmann A; Giesel F; Kratochwil C; Debus J; Jäger D; Mier W; Haberkorn U
J Nucl Med; 2018 Sep; 59(9):1415-1422. PubMed ID: 29626119
[TBL] [Abstract][Full Text] [Related]
13. Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention.
Loktev A; Lindner T; Burger EM; Altmann A; Giesel F; Kratochwil C; Debus J; Marmé F; Jäger D; Mier W; Haberkorn U
J Nucl Med; 2019 Oct; 60(10):1421-1429. PubMed ID: 30850501
[TBL] [Abstract][Full Text] [Related]
14. Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA
Moon ES; Elvas F; Vliegen G; De Lombaerde S; Vangestel C; De Bruycker S; Bracke A; Eppard E; Greifenstein L; Klasen B; Kramer V; Staelens S; De Meester I; Van der Veken P; Rösch F
EJNMMI Radiopharm Chem; 2020 Jul; 5(1):19. PubMed ID: 32728930
[TBL] [Abstract][Full Text] [Related]
15. Radioligands Targeting Fibroblast Activation Protein (FAP).
Lindner T; Giesel FL; Kratochwil C; Serfling SE
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830898
[TBL] [Abstract][Full Text] [Related]
16. Immuno-PET and Immuno-SPECT of Rheumatoid Arthritis with Radiolabeled Anti-Fibroblast Activation Protein Antibody Correlates with Severity of Arthritis.
Laverman P; van der Geest T; Terry SY; Gerrits D; Walgreen B; Helsen MM; Nayak TK; Freimoser-Grundschober A; Waldhauer I; Hosse RJ; Moessner E; Umana P; Klein C; Oyen WJ; Koenders MI; Boerman OC
J Nucl Med; 2015 May; 56(5):778-83. PubMed ID: 25858044
[TBL] [Abstract][Full Text] [Related]
17. Beyond Small Molecules: Antibodies and Peptides for Fibroblast Activation Protein Targeting Radiopharmaceuticals.
Sun X; Wu Y; Wang X; Gao X; Zhang S; Sun Z; Liu R; Hu K
Pharmaceutics; 2024 Feb; 16(3):. PubMed ID: 38543239
[TBL] [Abstract][Full Text] [Related]
18. Dual-time point
Parghane RV; Basu S
Semin Nucl Med; 2017 Jul; 47(4):373-391. PubMed ID: 28583277
[TBL] [Abstract][Full Text] [Related]
19. Abass Alavi: A giant in Nuclear Medicine turns 80 and is still going strong!
Høilund-Carlsen PF
Hell J Nucl Med; 2018; 21(1):85-87. PubMed ID: 29550853
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
